Demographic, disease and treatment findings at COVID-19 diagnosis
| All patients (n=110) | Admitted (n=35) | Died (n=18) | ||||
| Median age (range) years | 63 (27–86) | 65 (35–83) | 63 (42–81) | |||
| <65 | 58 | (53%) | 17 | (49%) | 9 | (50%) |
| ≥65 | 52 | (47%) | 18 | (51%) | 9 | (50%) |
| Sex | ||||||
| Female | 38 | (35%) | 11 | (32%) | 7 | (39%) |
| Male | 72 | (65%) | 24 | (68%) | 11 | (61%) |
| Region | ||||||
| Australia | 4 | (3%) | 1 | (3%) | 0 | (0%) |
| Europe | 70 | (64%) | 16 | (46%) | 5 | (27%) |
| Italy | 48 | (45%) | 6 | (17%) | 3 | (17%) |
| UK | 8 | (7%) | 5 | (14%) | 1 | (5%) |
| The Netherlands | 6 | (5%) | 2 | (6%) | 0 | (0%) |
| Germany | 4 | (3%) | 1 | (3%) | 0 | (0%) |
| France | 3 | (3%) | 2 | (6%) | 1 | (5%) |
| Switzerland | 1 | (1%) | 0 | (0%) | 0 | (0%) |
| North America | 36 | (33%) | 18 | (51%) | 13 | (73%) |
| USA | 29 | (27%) | 16 | (45%) | 11 | (62%) |
| Canada | 7 | (6%) | 2 | (6%) | 2 | (11%) |
| ICI treatment setting | ||||||
| (Neo)adjuvant | 27 | (25%) | 4 | (11%) | 0 | (0%) |
| Advanced | 83 | (75%) | 31 | (89%) | 18 | (100%) |
| Cancer type | ||||||
| Melanoma | 64 | (58%) | 17 | (49%) | 5 | (28%) |
| NSCLC | 17 | (16%) | 5 | (14%) | 4 | (22%) |
| RCC | 10 | (9%) | 4 | (11%) | 2 | (11%) |
| Other | 19 | (17%) | 9 | (26%) | 7 | (39%) |
| Coexisting disorder | ||||||
| None | 60 | (55%) | 21 | (60%) | 8 | (44%) |
| Cardiovascular | 30 | (27%) | 5 | (14%) | 2 | (11%) |
| Diabetes mellitus | 16 | (15%) | 6 | (17%) | 3 | (17%) |
| Pulmonary | 13 | (12%) | 5 | (14%) | 4 | (22%) |
| Renal | 6 | (5%) | 3 | (9%) | 3 | (17%) |
| ICI | ||||||
| Anti-PD-1/PD-L1 | 90 | (82%) | 23 | (66%) | 13 | (72%) |
| Anti-PD-1 plus anti-CTLA-4 | 16 | (15%) | 10 | (28%) | 4 | (22%) |
| Other* | 4 | (3%) | 2 | (6%) | 1 | (6%) |
| Previous chemotherapy | ||||||
| Yes | 25 | (23%) | 8 | (23%) | 6 | (33%) |
| No | 85 | (77%) | 27 | (77%) | 12 | (67%) |
| Response to ICI at COVID-19 diagnosis Adjuvant | ||||||
| NED | 4 | (4%) | 1 | (3%) | 0 | (0%) |
| Advanced | ||||||
| PR/CR | 29 | (26%) | 7 | (20%) | 3 | (17%) |
| SD | 20 | (18%) | 6 | (17%) | 4 | (22%) |
| PD | 17 | (16%) | 11 | (31%) | 6 | (33%) |
| Not reported | 40 | (36%) | 10 | (29%) | 5 | (28%) |
*Pembrolizumab–bevacizumab, pembrolizumab–anti-TIGIT, avelumab–axitinib, pembrolizumab–vopratelimab.
CR, complete response; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibition; NED, no evidence of disease; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-1, programmed cell death protein 1; PD-L1, programmed cell death-ligand 1; PR, partial response; RCC, renal cell carcinoma; SD, stable disease.